(Total Views: 785)
Posted On: 04/16/2020 7:59:45 PM
Post# of 148985
Remdesivir huge press attention, could be huge for Cytodyn! Why? The world is now talking about an alternative to vaccines and antiviral for the exact same reasons we have been excited about. Fantastic!
Don’t forget:
- Leronlimab does everything and more, and is safer!
- EIND results have been analyzed by Dr. P and will be publishing findings in 2 weeks. Proof of Leronlimab MOA and details of the virus’ disruption. Huge!!
- Leronlimab tests in process with “placebo” will bring us the next level of recognition by professionals in 4-6 weeks at the 50 patient interim results!
Today’s Gilead’s news was exciting but knowledgeable people were also raising caution flags until proper double blind placebo trials are done.
Bottom line, bring on the press focus! Gives us more of an opportunity to be recognized and shine!! I am even more excited now that Gilead has basically created a huge market opportunity for us. Nader has to leverage it properly, get the Docs and patients testimonials and promote the heck of Cytodyn as the placebo trials presents the final validation for Leronlimab.
Don’t forget:
- Leronlimab does everything and more, and is safer!
- EIND results have been analyzed by Dr. P and will be publishing findings in 2 weeks. Proof of Leronlimab MOA and details of the virus’ disruption. Huge!!
- Leronlimab tests in process with “placebo” will bring us the next level of recognition by professionals in 4-6 weeks at the 50 patient interim results!
Today’s Gilead’s news was exciting but knowledgeable people were also raising caution flags until proper double blind placebo trials are done.
Bottom line, bring on the press focus! Gives us more of an opportunity to be recognized and shine!! I am even more excited now that Gilead has basically created a huge market opportunity for us. Nader has to leverage it properly, get the Docs and patients testimonials and promote the heck of Cytodyn as the placebo trials presents the final validation for Leronlimab.
(9)
(0)Scroll down for more posts ▼
